Cited by 547Tuberculosis Research and EpidemiologyInfectious Diseases and TuberculosisHIV, TB, and STIs Epidemiology

The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.

The global prevalence of latent tuberculosis: a systematic review and meta-analysis

Open access

Cohen, Adam, Mathiasen, Victor Dahl, Schön, Thomas, Wejse, Christian·2019·European Respiratory Journal

DOI 10.1183/13993003.00655-2019

Open this paper in CoChat — free account Open PDF

Abstract

In 1999, the World Health Organization (WHO) estimated that one-third of the world's population had latent tuberculosis infection (LTBI), which was recently updated to one-fourth. However, this is still based on controversial assumptions in combination with tuberculin skin test (TST) surveys. Interferon-γ release assays (IGRAs) with a higher specificity than TST have since been widely implemented, but never used to estimate the global LTBI prevalence. We conducted a systematic review and meta-analysis of LTBI estimates based on both IGRA and TST results published between 2005 and 2018. Regional and global estimates of LTBI prevalence were calculated. Stratification was performed for low, intermediate and high TB incidence countries and a pooled estimate for each area was calculated using a random effects model. Among 3280 studies screened, we included 88 studies from 36 countries with 41 IGRA (n=67 167) and 67 TST estimates (n=284 644). The global prevalence of LTBI was 24.8% (95% CI 19.7–30.0%) and 21.2% (95% CI 17.9–24.4%), based on IGRA and a 10-mm TST cut-off, respectively. The prevalence estimates correlated well to WHO incidence rates (Rs=0.70, p<0.001). In the first study of the global prevalence of LTBI derived from both IGRA and TST surveys, we found that one-fourth of the world's population is infected. This is of relevance, as both tests, although imperfect, are used to identify individuals eligible for preventive therapy. Enhanced efforts are needed targeting the large pool of latently infected individuals, as this constitutes an enormous source of potential active tuberculosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1183/13993003.00655-2019

Cites

123 of 123 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
Elm, E. V., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · BMJ · doi:10.1136/bmj.39335.541782.ad · Cited by 10,766
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
Hill, N. R., Fatoba, S., Oke, J. L., Hirst, J. A., O’Callaghan, C. A., Lasserson, D. S., & Hobbs, R. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158765 · Cited by 4,320
Global Burden of Tuberculosis
Dye, C., Scheele, S., >Dolin, P., Pathania, V. S., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,955
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Houben, R. M. G. J., & Dodd, P. J. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002152 · Cited by 2,054
The Immune Response in Tuberculosis
O’Garra, A., Redford, P. S., McNab, F. W., Bloom, C. I., Wilkinson, R. J., & Berry, M. P. R. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095939 · Cited by 1,400

Show all 123 references

Research works printed but not linked: 2

Styblo, 1985, The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis, Bull Int Union Tuberc Lung Dis, 60, 117
Murthy, 2013, PLoS One, 8, e71470

Sorted by citations

Pathogenicity and virulence of Mycobacterium tuberculosis
Rahlwes, K. C., Dias, B., Campos, P. C., Álvarez-Arguedas, S., & Shiloh, M. U. (2022) · Virulence · doi:10.1080/21505594.2022.2150449 · Cited by 242
The definition of tuberculosis infection based on the spectrum of tuberculosis disease
Migliori, G. B., Ong, C. W. M., Petrone, L., D'Ambrosio, L., Centis, R., & Goletti, D. (2021) · Breathe · doi:10.1183/20734735.0079-2021 · Cited by 166
Latent Tuberculosis Infection
Shah, M., & Dorman, S. E. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2108501 · Cited by 145
Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung
Ogongo, P., Tezera, L. B., Ardain, A., Nhamoyebonde, S., Ramsuran, D., Singh, A., Ngoepe, A., Karim, F., Naidoo, T., Khan, K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142014 · Cited by 120
The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB)
Zellweger, J. P., Sotgiu, G., Corradi, M., & Durando, P. (2020) · La Medicina del Lavoro · doi:10.23749/mdl.v111i3.9983 · Cited by 122
Diagnostic biomarkers for active tuberculosis: progress and challenges
Nogueira, B. M. F., Krishnan, S., Barreto‐Duarte, B., Araújo‐Pereira, M., Queiroz, A. T. L., Ellner, J. J., Salgame, P. R., Scriba, T. J., Sterling, T. R., Gupta, A., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114088 · Cited by 106
Prevalence trends of latent tuberculosis infection at the global, regional, and country levels from 1990–2019
Ding, C., Hu, M., Guo, W., Hu, W., Li, X., Wang, S., Shangguan, Y., Zhang, Y., Yang, S., & Xu, K. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.05.029 · Cited by 101
Immune checkpoint inhibitors and tuberculosis: an old disease in a new context
Langan, E. A., Grätz, V., Allerheiligen, J., Zillikens, D., Rupp, J., & Terheyden, P. A. M. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30674-6 · Cited by 91
Clinical Development of New TB Vaccines: Recent Advances and Next Steps
Hatherill, M., White, R. G., & Hawn, T. R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03154 · Cited by 85
Mycobacterium tuberculosis : Pathogenesis and therapeutic targets
Yang, J., Zhang, L., Qiao, W., & Luo, Y. (2023) · MedComm · doi:10.1002/mco2.353 · Cited by 91
Clinical standards for the diagnosis, treatment and prevention of TB infection
Migliori, G. B., Wu, S., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., García‐Basteiro, A. L., et al. (2022) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0753 · Cited by 83
Improving Tuberculosis Medication Adherence: The Potential of Integrating Digital Technology and Health Belief Model
Sazali, M. F., Rahim, S. S. S. A., Mohammad, A. H., Kadir, F. B. M., Payus, A. O., Avoi, R., Jeffree, M. S., Omar, A., Ibrahim, M. Y., Atil, A., et al. (2023) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2022.0148 · Cited by 95
Structure of an endogenous mycobacterial MCE lipid transporter
Chen, J., Fruhauf, A., Fan, C., Ponce, J., Ueberheide, B., Bhabha, G., & Ekiert, D. C. (2023) · Nature · doi:10.1038/s41586-023-06366-0 · Cited by 69
From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning
Li, L., Yang, L., Li, Z., Ye, Z., Zhao, W., & Gong, W. (2023) · Military Medical Research · doi:10.1186/s40779-023-00490-8 · Cited by 80
Cytokine storm in tuberculosis and IL-6 involvement
Boni, F. G., Hamdi, I., Koundi, L. M., Shrestha, K., & Xie, J. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105166 · Cited by 68
Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis
Rustage, K., Lobe, J., Hayward, S. E., Kristensen, K. L., Margineanu, I., Stienstra, Y., Goletti, D., Zenner, D., Noori, T., Pareek, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00052-9 · Cited by 67
Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy
Chang, D. P. S., & Guan, X. L. (2021) · Metabolites · doi:10.3390/metabo11020088 · Cited by 70
Microbiome-immune interactions in tuberculosis
Mori, G., Morrison, M., & Blumenthal, A. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009377 · Cited by 80
Machine learning based on routine laboratory indicators promoting the discrimination between active tuberculosis and latent tuberculosis infection
Luo, Y., Xue, Y., Song, H., Tang, G., Liu, W., Bai, H., Xu, Y., Tong, S., Wang, F., Cai, Y., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2021.12.046 · Cited by 64
Diagnosis of tuberculosis: a consensus statement from the Brazilian Thoracic Association
Silva, D. R., Rabahi, M. F., Sant’Anna, C. C., Júnior, J. L. R. D. S., Capone6, D., Bombarda, S., de Miranda, S. S., da Rocha, J. L., Dalcolmo, M. P., Rick, M. F., et al. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210054 · Cited by 58
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?
Dowdy, D. W., & Behr, M. A. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00153-0 · Cited by 58
Repurposing Immunomodulatory Drugs to Combat Tuberculosis
Fatima, S., Bhaskar, A., & Dwivedi, V. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645485 · Cited by 58
Global, regional, and national burden of HIV-negative tuberculosis, 1990–2021: findings from the Global Burden of Disease Study 2021
Zhang, S.-X., Miao, F.-Y., Yang, J., Zhou, W., Lv, S., Wei, F.-N., Wang, Y., Hu, X., Yin, P., Zheng, P., et al. (2024) · Infectious Diseases of Poverty · doi:10.1186/s40249-024-01227-y · Cited by 57
Clinical features of tuberculous lymphadenitis in a low-incidence country
Mathiasen, V. D., Andersen, P. H., Johansen, I. S., Lillebaek, T., & Wejse, C. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.07.011 · Cited by 56
Self-citation
The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse
Shu, C., Liao, K., Chen, Y., Wang, J., & Ho, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-48395-8 · Cited by 56
Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection
Petruccioli, E., Chiacchio, T., Navarra, A., Vanini, V., Cuzzi, G., Cimaglia, C., Codecasa, L. R., Pinnetti, C., Riccardi, N., Palmieri, F., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.02.009 · Cited by 56
Diabetes mellitus and tuberculosis, a systematic review and meta-analysis with sensitivity analysis for studies comparable for confounders
Foe-Essomba, J. R., Kenmoe, S., Tchatchouang, S., Ebogo‐Belobo, J. T., Mbaga, D. S., Kengne-Ndé, C., Mahamat, G., Kame‐Ngasse, G. I., Noura, E. A., Mikangue, C. A. M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261246 · Cited by 58
The Role of Fatty Acid Metabolism in Drug Tolerance of Mycobacterium tuberculosis
Quinonez, C. G., Lee, J. J., Lim, J., Odell, M., Lawson, C. P. A. T., Anyogu, A., Raheem, S., & Eoh, H. (2022) · mBio · doi:10.1128/mbio.03559-21 · Cited by 56
Prevalence and factors associated with tuberculosis infection in India
Selvaraju, S., Velayutham, B., Rao, R., Rade, K., Thiruvengadam, K., Asthana, S., Balachandar, R., Bangar, S. D., Bansal, A. K., Bhat, J., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.10.009 · Cited by 64
The path to tuberculosis elimination: a renewed vision
Migliori, G. B., Dowdy, D. W., Denholm, J. T., D’Ambrosio, L., & Centis, R. (2023) · European Respiratory Journal · doi:10.1183/13993003.00499-2023 · Cited by 51
Cigarette Smoking as a Risk Factor for Tuberculosis in Adults: Epidemiology and Aspects of Disease Pathogenesis
Feldman, C. H., Theron, A. J., Cholo, M. C., & Anderson, R. (2024) · Pathogens · doi:10.3390/pathogens13020151 · Cited by 51
Antigen-Specific T-Cell Activation Distinguishes between Recent and Remote Tuberculosis Infection
Mpande, C. A. M., Musvosvi, M., Rozot, V., Mosito, B., Reid, T. D., Schreuder, C., Lloyd, T., Bilek, N., Huang, H., Obermoser, G., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202007-2686oc · Cited by 51
Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries
Abri, S. A., Kasaeva, T., Migliori, G. B., Goletti, D., Zenner, D., Denholm, J. T., Al-Maani, A. S., Cirillo, D. M., Schön, T., Lillebæk, T., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.02.042 · Cited by 49
Self-citation
Diabetes-Associated Susceptibility to Tuberculosis: Contribution of Hyperglycemia vs. Dyslipidemia
Ngo, M. D., Bartlett, S., & Ronacher, K. (2021) · Microorganisms · doi:10.3390/microorganisms9112282 · Cited by 50
MicroRNAs as diagnostic biomarkers for Tuberculosis: A systematic review and meta- analysis
Daniel, E. A., Sathiyamani, B., Thiruvengadam, K., Vivekanandan, S., Vembuli, H., & Hanna, L. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954396 · Cited by 41
Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection
Xu, W., Snell, L. M., Guo, M., Boukhaled, G. M., Macleod, B. L., Li, M., Tullius, M. V., Guidos, C. J., Tsao, M., Divangahi, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.003 · Cited by 40
Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review
Kiran, D., & Basaraba, R. J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.624607 · Cited by 39
Active case-finding of tuberculosis in general populations and at-risk groups: a systematic review and meta-analysis
Bohlbro, A. S., Hvingelby, V. S., Rudolf, F., Wejse, C. M., & Patsche, C. B. (2021) · European Respiratory Journal · doi:10.1183/13993003.00090-2021 · Cited by 40
Self-citation
The Association Between Diabetes Mellitus and the Risk of Latent Tuberculosis Infection: A Systematic Review and Meta-Analysis
Liu, Q., Yan, W., Runqing, L., Bo, E., Liu, J., & Liu, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.899821 · Cited by 40
Nationwide tuberculosis outbreak in the USA linked to a bone graft product: an outbreak report
Schwartz, N. G., Hernández-Romieu, A. C., Annambhotla, P. D., Filardo, T. D., Althomsons, S. P., Free, R. J., Li, R., Wilson, W. W., Deutsch-Feldman, M., Drees, M. L., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00425-x · Cited by 40
Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis
Delemarre, E. M., van Hoorn, L., Bossink, A. W. J., Drylewicz, J., Joosten, S. A., Ottenhoff, T. H. M., Akkerman, O. W., Goletti, D., Petruccioli, E., Navarra, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.725447 · Cited by 39
Prevalence and risk factors associated with latent tuberculosis infection among household contacts of smear positive pulmonary tuberculosis patients in South India
Krishnamoorthy, Y., Ezhumalai, K., Murali, S., Rajaa, S., Jose, M., Sathishkumar, A., Soundappan, G., Horsburgh, C. R., Hochberg, N. S., Johnson, W. E., et al. (2021) · Tropical Medicine & International Health · doi:10.1111/tmi.13693 · Cited by 39
Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
Min, H. K., Kim, S. H., Kim, H., & Lee, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213913 · Cited by 38
Indeterminate results of interferon gamma release assays in the screening of latent tuberculosis infection: a systematic review and meta-analysis
Zhou, G., Luo, Q., Luo, S., Chen, H., Cai, S., Guo, X., He, J. F., Xia, Y., Li, H., Zhou, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170579 · Cited by 38
Biomarkers and immunological tests. Experimental and clinical parallels of latent tuberculosis infection
Kuday, D. A. (2020) · Tuberculosis and lung diseases · doi:10.21292/2075-1230-2020-98-8-63-74 · Cited by 38
Positive rates of interferon-γ release assay and tuberculin skin test in detection of latent tuberculosis infection: A systematic review and meta-analysis of 200,000 head-to-head comparative tests
Zhou, G., Luo, Q., Luo, S., He, J. F., Chen, N., Zhang, Y., Yang, R., Qiu, Y., Li, S., Ping, Q., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109132 · Cited by 37
Sex differences in the risk of Mycobacterium tuberculosis infection: a systematic review and meta-analysis of population-based immunoreactivity surveys
Rickman, H. M., Phiri, M. D., Feasey, H. R. A., Krutikov, M., Shao, H., Horton, K. C., Dowdy, D. W., Nightingale, E., Dodd, P. J., Corbett, E. L., et al. (2025) · The Lancet Public Health · doi:10.1016/s2468-2667(25)00120-3 · Cited by 36
The Mtb -HIV Syndemic Interaction: Why Treating M. tuberculosis Infection May Be Crucial for HIV-1 Eradication
Waters, R., Ndengane, M., Abrahams, M.-R., Diedrich, C. R., Wilkinson, R. J., & Coussens, A. K. (2020) · Future Virology · doi:10.2217/fvl-2019-0069 · Cited by 35
Clinical profiles of subclinical disease among pulmonary tuberculosis patients: a prospective cohort study in South Korea
Min, J., Chung, C., Jung, S. S., Park, H. K., Lee, S.-S., & Lee, K. M. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01351-z · Cited by 36
Tuberculosis in individuals who recovered from COVID-19: A systematic review of case reports
Alemu, A., Bitew, Z. W., Seid, G., Diriba, G., Gashu, E., Berhe, N., Mariam, S. H., & Gumi, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277807 · Cited by 36
Reverse vaccinology approach to design a multi-epitope vaccine construct based on the Mycobacterium tuberculosis biomarker PE_PGRS17
Moodley-Reddy, A., Fatoba, A. J., Okpeku, M., Chiliza, T. E., Simelane, M. B. C., & Pooe, O. J. (2022) · Immunologic Research · doi:10.1007/s12026-022-09284-x · Cited by 35
The economics of malnutrition: Dietary transition and food system transformation
Masters, W. A., Finaret, A. B., & Block, S. (2022) · Handbook of agricultural economics · doi:10.1016/bs.hesagr.2022.03.006 · Cited by 44
Tuberculosis in childhood and adolescence: a view from different perspectives
Tahan, T. T., Gabardo, B. M. A., & Rossoni, A. M. D. O. (2019) · Jornal de Pediatria · doi:10.1016/j.jped.2019.11.002 · Cited by 34
First clinical evaluation of the QIAreach TM QuantiFERON-TB for tuberculosis infection and active pulmonary disease
Fukushima, K., Akagi, K., Kondo, A., Kubo, T., Sakamoto, N., & Mukae, H. (2021) · Pulmonology · doi:10.1016/j.pulmoe.2021.07.003 · Cited by 34
Micro RNAs as potential biomarkers in tuberculosis: A systematic review
PATTNAIK, B. R., Patnaik, N., Mittal, S., Mohan, A., Agrawal, A., Guleria, R., & Madan, K. (2022) · Non-coding RNA Research · doi:10.1016/j.ncrna.2021.12.005 · Cited by 35
Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection
Chin, K. L., Anibarro, L., Sarmiento, M. E., & Acosta, A. (2023) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed8020089 · Cited by 32
Tuberculosis Infection in Pregnant People: Current Practices and Research Priorities
Mathad, J. S., Yadav, S., Vaidyanathan, A., Gupta, A., & LaCourse, S. M. (2022) · Pathogens · doi:10.3390/pathogens11121481 · Cited by 32
Ending tuberculosis: challenges and opportunities
Gilmour, B., & Alene, K. A. (2024) · Frontiers in Tuberculosis · doi:10.3389/ftubr.2024.1487518 · Cited by 32
Towards more accurate 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging in active and latent tuberculosis
Priftakis, D., Riaz, S., Zumla, A. I., & Bomanji, J. B. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.02.017 · Cited by 31
Worldwide prevalence of human papillomavirus among pregnant women: A systematic review and meta‐analysis
Ardekani, A., Sepidarkish, M., Mollalo, A., Afradiasbagharani, P., Rouholamin, S., Rezaeinejad, M., Farid‐Mojtahedi, M., Mahjour, S., Almukhtar, M., Shiadeh, M. N., et al. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2374 · Cited by 35
Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Choi, Y. H., Kang, Y. A., Park, K. J., Choi, J. C., Cho, K. G., Ko, D. Y., Ahn, J. H., Lee, B., Ahn, E., Woo, Y. J., et al. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00806-0 · Cited by 30
The use of the ELISPOT technological platform in the diagnosis of tuberculosis infection in patients with HIV infection
Бородулина, Е. А., Kudlay, D. A., Kuznetsova, A. N., Гладунова, Е. П., & Kalashnikova, E. V. (2021) · Immunologiya · doi:10.33029/0206-4952-2021-42-4-395-402 · Cited by 29
Advances in immunomodulatory strategies for host-directed therapies in combating tuberculosis
Ayodele, S., Kumar, P., Eyk, A. D. V., & Choonara, Y. E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114588 · Cited by 29
Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review
Chihota, V. N., Gombe, M., Gupta, A., Salazar‐Austin, N., Ryckman, T. S., Hoffmann, C. J., LaCourse, S. M., Mathad, J. S., Mave, V., Dooley, K. E., et al. (2024) · Drugs · doi:10.1007/s40265-024-02131-3 · Cited by 29
Historical review of studies on the effect of treating latent tuberculosis
Mølhave, M., & Wejse, C. M. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.011 · Cited by 29
Self-citation
Protein target highlights in CASP15 : Analysis of models by structure providers
Alexander, L. T., Durairaj, J., Kryshtafovych, A., Abriata, L. A., Bayo, Y., Bhabha, G., Breyton, C., Caulton, S. G., Chen, J., Degroux, S., et al. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26545 · Cited by 28
War in Ukraine: an immense threat to the fight against tuberculosis
Dahl, V. N., Migliori, G. B., Lange, C. G., & Wejse, C. M. (2022) · European Respiratory Journal · doi:10.1183/13993003.00493-2022 · Cited by 28
Self-citation
Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors – A nationwide population-based cohort study
Kim, H. W., Kim, J. S., & Lee, S. H. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.034 · Cited by 27
Lymphocyte-Related Immunological Indicators for Stratifying Mycobacterium tuberculosis Infection
Luo, Y., Xue, Y., Tang, G., Cai, Y., Xu, Y., Lin, Q., Song, H., Liu, W., Mao, L., Zhou, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658843 · Cited by 27
Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection
Canales, C. S. C., Cazorla, J. I. M., Torres, A. H. F., Filardi, E. T. M., Filippo, L. D. D., da Costa, P. I., Roque‐Borda, C. A., & Pavan, F. R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102409 · Cited by 27
Novel serological biomarker panel using protein microarray can distinguish active TB from latent TB infection
Li, J., Wang, Y., Yan, L., Zhang, C., He, Y., Zou, J., Zhou, Y., Zhong, C., & Zhang, X. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2022.105002 · Cited by 26
Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials
Assefa, D. G., Bedru, A., Zeleke, E. D., Negash, S. E., Debela, D. T., Molla, W., Mengistu, N., Woldesenbet, T. T., Bedane, N. F., Kajogoo, V. D., et al. (2023) · Archives of Public Health · doi:10.1186/s13690-023-01098-z · Cited by 26
Prevalence of latent tuberculosis infection in Asian nations: A systematic review and meta‐analysis
Shrestha, A. B., Siam, I. S., Tasnim, J., Dahal, A., Roy, P., Neupane, S., Adhikari, A., Khanal, B., Ghimirie, R., Shrestha, D., et al. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1200 · Cited by 27
Lipid droplets and the transcriptome of Mycobacterium tuberculosis from direct sputa: a literature review
Mekonnen, D. S., Derbie, A., Mihret, A., Yimer, S. A., Tønjum, T., Gelaw, B., Nibret, E., Munshae, A., Waddell, S. J., & Aseffa, A. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01550-5 · Cited by 26
A combination of iron metabolism indexes and tuberculosis-specific antigen/phytohemagglutinin ratio for distinguishing active tuberculosis from latent tuberculosis infection
Luo, Y., Xue, Y., Lin, Q., Tang, G., Xu, Y., Mao, L., Song, H., Wang, F., & Sun, Z. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.05.109 · Cited by 24
Activation Phenotype of Mycobacterium tuberculosis-Specific CD4+ T Cells Promoting the Discrimination Between Active Tuberculosis and Latent Tuberculosis Infection
Luo, Y., Xue, Y., Mao, L., Lin, Q., Tang, G., Song, H., Liu, W., Tong, S., Hou, H., Huang, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.721013 · Cited by 24
The Impact of Borderline Quantiferon-TB Gold Plus Results for Latent Tuberculosis Screening under Routine Conditions in a Low-Endemicity Setting
Wikell, A., Jonsson, J., Dyrdak, R., Henningsson, A. J., Eringfält, A., Kjerstadius, T., Hålldin, E., Baqir, H., Kholod, V., Sturegård, E., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01370-21 · Cited by 24
Self-citation
Comparison of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold-Plus in the Diagnosis of Mycobacterium tuberculosis Infections in Immunocompromised Patients: a Real-World Study
Xu, Y., Yang, Q., Zhou, J., Zhou, F., Hezhang, Y., Gao, Y., Shao, L., Shi, J., Ruan, Q., & Zhang, W. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01870-21 · Cited by 24
Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges
Agbota, G., Bonnet, M., & Lienhardt, C. (2023) · Pathogens · doi:10.3390/pathogens12030362
Anti- Mycobacterium paratuberculosis (MAP) therapy for Crohn’s disease: an overview and update
Honap, S., Johnston, E., Agrawal, G. K., Al-Hakim, B., Hermon-Taylor, J., & Sanderson, J. D. (2020) · Frontline Gastroenterology · doi:10.1136/flgastro-2020-101471 · Cited by 24
Cost-effectiveness of IGRA/QFT-Plus for TB screening of migrants in Oman
Abri, S. A., Kowada, A., Yaqoubi, F. A., Khalili, S. A., Ndunda, N., & Petersen, E. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.010 · Cited by 23
QuantiFERON-TB Gold Plus with Chemiluminescence Immunoassay: Do We Need a Higher Cutoff?
Bisognin, F., Lombardi, G., Re, M. C., & Monte, P. D. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00780-20 · Cited by 23
Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors
Alexandrova, L. A., Khandazhinskaya, A. L., Matyugina, E. S., Makarov, D. A., & Kochetkov, S. N. (2022) · Microorganisms · doi:10.3390/microorganisms10071299 · Cited by 24
Preventive Treatment for Household Contacts of Drug-Susceptible Tuberculosis Patients
Salazar‐Austin, N., Mulder, C., Hoddinott, G., Ryckman, T. S., Hanrahan, C. F., Velen, K., Chimoyi, L., Charalambous, S., & Chihota, V. N. (2022) · Pathogens · doi:10.3390/pathogens11111258 · Cited by 26
PET-CT-guided characterisation of progressive, preclinical tuberculosis infection and its association with low-level circulating Mycobacterium tuberculosis DNA in household contacts in Leicester, UK: a prospective cohort study.
Kim, J., Bowman, K., Nazareth, J., Lee, J., Woltmann, G., Verma, R., Sharifpour, M., Shield, C. G., Rees, C. E. D., Kamil, A., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00289-6 · Cited by 16
Dissecting Host-Pathogen Interactions in TB Using Systems-Based Omic Approaches
Borah, K., Xu, Y., & McFadden, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762315 · Cited by 22
Video-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis
Truong, B., Tanni, K. A., & Qian, J. (2021) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.10.013 · Cited by 22
Armed conflict and human displacement may lead to an increase in the burden of tuberculosis in Europe
Dahl, V. N., Tiberi, S., Goletti, D., & Wejse, C. M. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.040 · Cited by 22
Self-citation
Efficacy of anti-tuberculosis drugs for the treatment of latent tuberculosis infection: a systematic review and network meta-analysis
Yoopetch, P., Anothaisintawee, T., Gunasekara, A. D. M., Jittikoon, J., Udomsinprasert, W., Thavorncharoensap, M., Youngkong, S., Thakkinstian, A., & Chaikledkaew, U. (2023) · Scientific Reports · doi:10.1038/s41598-023-43310-8 · Cited by 22
Persistent Mycobacterium tuberculosis bioaerosol release in a tuberculosis-endemic setting
Dinkele, R., Gessner, S., Patterson, B., McKerry, A., Hoosen, Z., Vazi, A., Seldon, R., Koch, A. S., Warner, D. F., & Wood, R. (2024) · iScience · doi:10.1016/j.isci.2024.110731 · Cited by 23
Combination of Blood Routine Examination and T-SPOT.TB Assay for Distinguishing Between Active Tuberculosis and Latent Tuberculosis Infection
Luo, Y., Tang, G., Xu, Y., Lin, Q., Mao, L., Song, H., Xue, Y., Wu, S., Ouyang, R., Hou, H., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.575650 · Cited by 21
Prevalence and risk factors of latent tuberculosis infection among college students: a systematic review and meta-analysis
Yuan, Y., Wang, X., Zhou, Y., Zhou, C., & Li, S. (2022) · Public Health · doi:10.1016/j.puhe.2022.10.003 · Cited by 21
High proportion of RR-TB and mutations conferring RR outside of the RRDR of the rpoB gene detected in GeneXpert MTB/RIF assay positive pulmonary tuberculosis cases, in Addis Ababa, Ethiopia
Akalu, G. T., Tessema, B., & Petros, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277145 · Cited by 21
Combination of prealbumin and tuberculosis‐specific antigen/phytohemagglutinin ratio for discriminating active tuberculosis from latent tuberculosis infection
Luo, Y., Xue, Y., Xu, Y., Lin, Q., Tang, G., Mao, L., Song, H., Wang, F., & Sun, Z. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13831 · Cited by 21
Risk of progression to active tuberculosis for indeterminate interferon-gamma release assay in immunocompromised individuals: a systematic review and meta-analysis
Zhou, G., Luo, S., He, J. F., Chen, N., Zhang, Y., Cai, S., Guo, X., & Song, C. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.07.003 · Cited by 20
Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon
Kufa, M., Finger, V., Kovar, O., Soukup, O., Torruellas, C., Roh, J., & Korábečný, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.01.023 · Cited by 25
In-vitro and ex-vivo characterization of novel mannosylated gelatin nanoparticles of linezolid by quality-by-design approach
Patil, K. D., Bagade, S. B., & Bonde, S. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101976 · Cited by 20
A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis
Chavas, T. E. J., Su, F., Srinivasan, S., Roy, D., Lee, B., Lovelace-Macon, L., Rerolle, G. F., Limqueco, E., Skerrett, S. J., Ratner, D. M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.031 · Cited by 20
Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis
Stieber, F., Howard, J., Manissero, D., Boyle, J., Ndunda, N., Love, J., Yang, M., Schumacher, A., Uchiyama, R., Parsons, S., et al. (2021) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0391 · Cited by 20
Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review)
Egorova, A., Salina, E. G., & Makarov, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413317 · Cited by 21

Authors: Cohen, A., Mathiasen, V. D., Schön, T., & Wejse, C.
Affiliations: St Olav's University Hospital (NO)
Linköping University (SE)
Bandim Health Project (GW)
ORCID: Cohen, Adam
Mathiasen, Victor Dahl
Schön, Thomas
Wejse, Christian
Venue: European Respiratory Journal
Publisher: European Respiratory Society (ERS)
Published: 2019-06-20
Volume: 54
Issue: 3
Pages: 1900655
ISSN: 0903-1936 (ISSN-L)
1399-3003
DOI: 10.1183/13993003.00655-2019
OpenAlex: W2950875755
Cited by: 547
References: 123
Citations by year: 2026: 61 · 2025: 78 · 2024: 94 · 2023: 89 · 2022: 101 · 2021: 73 · 2020: 47 · 2019: 4
FWCI: 7.86
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.ersjournals.com/user-licence (vor)
Locations: European Respiratory Journal (publishedVersion)
PubMed (publishedVersion)
Funders: Novo Nordisk (NNF15OC0018034)
Hjärt-Lungfonden (20150236)
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (201602043)
Topics: Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
Keywords: latent tuberculosis infection, global prevalence, interferon-gamma release assay, tuberculin skin test, tuberculosis prophylaxis
MeSH terms: Algorithms, Communicable Disease Control, Humans, Tuberculin Test, Global Health, World Health Organization, Incidence, Prevalence, Latent Tuberculosis, Interferon-gamma Release Tests

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The global prevalence of latent tuberculosis: a systematic review and meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks